These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22327430)

  • 1. Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity.
    Liu XY; Pop LM; Schindler J; Vitetta ES
    MAbs; 2012; 4(1):57-68. PubMed ID: 22327430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage.
    Baluna R; Coleman E; Jones C; Ghetie V; Vitetta ES
    Exp Cell Res; 2000 Aug; 258(2):417-24. PubMed ID: 10896793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.
    Mansfield E; Amlot P; Pastan I; FitzGerald DJ
    Blood; 1997 Sep; 90(5):2020-6. PubMed ID: 9292538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome.
    Baluna R; Rizo J; Gordon BE; Ghetie V; Vitetta ES
    Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3957-62. PubMed ID: 10097145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy.
    Amlot PL; Stone MJ; Cunningham D; Fay J; Newman J; Collins R; May R; McCarthy M; Richardson J; Ghetie V
    Blood; 1993 Nov; 82(9):2624-33. PubMed ID: 8219217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas.
    Shen GL; Li JL; Ghetie MA; Ghetie V; May RD; Till M; Brown AN; Relf M; Knowles P; Uhr JW
    Int J Cancer; 1988 Nov; 42(5):792-7. PubMed ID: 3263328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity and efficacy of anti-T-cell ricin toxin A chain immunotoxins in a murine model of established graft-versus-host disease induced across the major histocompatibility barrier.
    Vallera DA; Carroll SF; Snover DC; Carlson GJ; Blazar BR
    Blood; 1991 Jan; 77(1):182-94. PubMed ID: 1984794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice.
    Van Horssen PJ; Preijers FW; Van Oosterhout YV; De Witte T
    Int J Cancer; 1996 Nov; 68(3):378-83. PubMed ID: 8903481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.
    Ghetie MA; Tucker K; Richardson J; Uhr JW; Vitetta ES
    Blood; 1992 Nov; 80(9):2315-20. PubMed ID: 1384801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice.
    Smallshaw JE; Ghetie V; Rizo J; Fulmer JR; Trahan LL; Ghetie MA; Vitetta ES
    Nat Biotechnol; 2003 Apr; 21(4):387-91. PubMed ID: 12627168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome.
    Soler-Rodríguez AM; Ghetie MA; Oppenheimer-Marks N; Uhr JW; Vitetta ES
    Exp Cell Res; 1993 Jun; 206(2):227-34. PubMed ID: 8388800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability and cytotoxicity of Fab-ricin A immunotoxins prepared with water soluble long chain heterobifunctional crosslinking agents.
    Woo BH; Lee JT; Park MO; Lee KR; Han JW; Park ES; Yoo SD; Lee KC
    Arch Pharm Res; 1999 Oct; 22(5):459-63. PubMed ID: 10549572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life.
    Pop LM; Liu X; Ghetie V; Vitetta ES
    Int Immunopharmacol; 2005 Jul; 5(7-8):1279-90. PubMed ID: 15914332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study.
    Sausville EA; Headlee D; Stetler-Stevenson M; Jaffe ES; Solomon D; Figg WD; Herdt J; Kopp WC; Rager H; Steinberg SM
    Blood; 1995 Jun; 85(12):3457-65. PubMed ID: 7780133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An in vitro model for toxin-mediated vascular leak syndrome: ricin toxin A chain increases the permeability of human endothelial cell monolayers.
    Lindstrom AL; Erlandsen SL; Kersey JH; Pennell CA
    Blood; 1997 Sep; 90(6):2323-34. PubMed ID: 9310483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
    Wayne AS; Kreitman RJ; Findley HW; Lew G; Delbrook C; Steinberg SM; Stetler-Stevenson M; Fitzgerald DJ; Pastan I
    Clin Cancer Res; 2010 Mar; 16(6):1894-903. PubMed ID: 20215554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia.
    Barta SK; Zou Y; Schindler J; Shenoy N; Bhagat TD; Steidl U; Verma A
    Leuk Lymphoma; 2012 Oct; 53(10):1999-2003. PubMed ID: 22448921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hepatocellular carcinoma in a mouse xenograft model with an immunotoxin which is engineered to eliminate vascular leak syndrome.
    Wang H; Song S; Kou G; Li B; Zhang D; Hou S; Qian W; Dai J; Tian L; Zhao J; Guo Y
    Cancer Immunol Immunother; 2007 Nov; 56(11):1775-83. PubMed ID: 17431617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An in vivo model to study immunotoxin-induced vascular leak in human tissue.
    Baluna R; Vitetta ES
    J Immunother; 1999 Jan; 22(1):41-7. PubMed ID: 9924698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro.
    Herrera L; Farah RA; Pellegrini VA; Aquino DB; Sandler ES; Buchanan GR; Vitetta ES
    Leukemia; 2000 May; 14(5):853-8. PubMed ID: 10803517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.